BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:As the TPD field eagerly awaits the approval of Arvinas's Vepd
 egestrant\, and with C4 Therapeutics and Kymera progressing through Phase
  1 and 2 clinical trials\, 2025 is poised to be the year of clinical vali
 dation for TPD. This has been echoed in the flurry of partnerships worth 
 over $200M in 2025 alone\, with the majority of big pharma now invested i
 n molecular glues\, PROTACs\, or novel induced proximity drugs.\n\nReturn
 ing as the industry's definitive forum from early discovery to clinical d
 evelopment\, the 8th Annual TPD and Induced Proximity Summit is the world
 's largest and longest-standing forum for proximity-based modalities\, en
 abling you to fully immerse yourself in the breadth and depth of cutting-
 edge induced proximity therapeutic development.\n\nFeaturing key leaders 
 such as Arvinas\, Nurix Therapeutics\, C4 Therapeutics\, and innovative n
 ewcomers including Larkspur Bio\, Magnet Biomedicine\, TrimTech Therapeut
 ics\, as well as the co-founders of TPD\, Craig Crews and Ray Deshaies\, 
 this is your ultimate meeting to hear the latest clinical data\, forge st
 rategic relationships\, and capitalize on the huge opportunity for this m
 odality to treat patients with high unmet clinical need.\n\nDate and Time
 : Monday\, 27 October 2025 at 07:30 to Thursday\, 30 October 2025 at 17:0
 0\n
DTEND:20251030T170000
DTSTAMP:20260514T153501Z
DTSTART:20251027T073000
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\,
  Massachusetts\, 02210\,
SEQUENCE:0
SUMMARY:As the TPD field eagerly awaits the approval of Arvinas's Vepdeges
 trant\, and with C4 Therapeutics and Kymera progressing through Phase 1 a
 nd 2 clin...
UID:ed39e48e-034e-44b3-b0d1-ec91995f9683
END:VEVENT
END:VCALENDAR